NEW YORK, Feb. 17, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
AxoGen, Inc. (NASDAQ: AXGN)
Class Period: August 7, 2017 - December 18, 2018
Lead Plaintiff Deadline: March 11, 2019
Join the action: https://www.zlk.com/pslra-1/axogen-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, AxoGen, Inc. allegedly made materially false and/or misleading statements and/or
failed to disclose that: (1) the Company aggressively increased prices to mask lower sales; (2) the Company’s pricing alienated
customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the
Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number
of surgeons whom the Company paid to generate sales; (6) the Company’s consignment model for inventory was reasonably likely to
lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8)
the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked
adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics,
such as number of active accounts, were overstated; and (11) as a result of the foregoing, Defendants’ positive statements about
the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the AxoGen, Inc. class action contact jlevi@levikorsinsky.com.
Tyme Technologies, Inc. (NASDAQCM: TYME)
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3
About the lawsuit: During the class period, Tyme Technologies, Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy
of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical
trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88
in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant
times.
To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com.
Maiden Holdings, Ltd. (NASDAQGS: MHLD)
Class Period: March 4, 2014 - November 9, 2018
Lead Plaintiff Deadline: April 12, 2019
Join the action: https://www.zlk.com/pslra-1/maiden-holdings-ltd-loss-form?wire=3
The complaint alleges that during the Class Period, defendants misrepresented the quality and nature of Maiden’s underwriting
and risk management policies and practices and the risks of its reinsurance portfolio. In particular, defendants misleadingly
claimed that they were subjecting AmTrust’s insurance portfolio to robust analysis and cross-checks to ensure that the Company had
appropriately priced the risk of reinsuring AmTrust’s insurance portfolio. In truth, the Company had failed to employ sufficient
underwriting and risk management protocols and had largely abdicated its responsibility to ensure that its AmTrust Reinsurance
segment priced policies commensurate with the risk assumed by the Company.
To learn more about the Maiden Holdings, Ltd. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
